NSNeslihan Sönmez

Neslihan Sönmez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Neslihan Sönmez has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Phytochemical Investigation of Rumex olympicus Boiss.: Isolation of Two Catechins and an Anthraquinone

    by Zuhal Güvenalp, Neslihan Sönmez, Zeynep İnCe, Ayşe Cemre Kararenk, Hilal Özbek, Cavit Kazaz, Ömür Demirezer

    Objective: The genus Rumex is represented by 25 species in the flora of Türkiye and is characterized by the presence of anthranoids, flavonoids, tannins, and naphthalene derivatives. In addition to their use as food, Rumex species are traditionally recognized for their laxative, wound-healing, and diuretic properties. This study aims to investigate the phytochemical constituents of Rumex olympicus Boiss. and to contribute the chemical characterization of the genus.Methods: Within the scope of the study, the roots, leaves, and fruiting inner perianth parts of Rumex olympicus were separately collected and dried. Among these, the fruiting inner perianth parts were selected for phytochemical investigation, and isolation procedures were carried out on the ethyl acetate extract. Results: As a result of the phytochemical investigations, tannin derivatives catechin, epicatechin-3′-O-gallate, and the anthraquinone derivative emodin-8-β-D-glucoside were isolated from the fruiting inner perianth parts of Rumex olympicus Boiss.Conclusion: The findings of this study contribute to the phytochemical profile of Rumex olympicus and support the presence of bioactive secondary metabolites within the genus. These results may provide a scientific basis for further pharmacological studies and potential applications of this endemic species.

  • Open Access

    Structure-activity relationship of anticancer drug candidate quinones

    by Nadire Özenver, Neslihan Sönmez, Merve Yüzbaşıoğlu Baran, Ayşe UZ, Lütfiye Ömür Demi̇rEzer

    Breast cancer is one of the most prevalent cancer types worldwide. Chemotherapy is a substantial approach in the management of breast cancer despite the occurrence of chemotherapy-associated side effects and the development of multidrug resistance in cancer cells. At this point, a variety of quinone derivatives may represent potential as possible anticancer drug candidates due to possessing structural similarity towards clinically used anticancer drugs like doxorubicin. Therefore, we investigated the cytotoxic effects of various quinone derivatives with structural diversity towards a variety of breast cancer cells. We further determined their toxicity in healthy cells to evaluate their drug capability potential. Eighteen quinone derivatives (arbutin, hydroquinone, alkannin, lapachol, lawsone, juglone, aloe-emodin, aloin, cascaroside A (8-O-β-D-glucoside of 10-C-β-D-glucosyl aloe-emodin anthrone), chrysophanol, chrysophanol-8-O-β-D-glucoside, emodin, emodin-8-O-β-D-glucoside, frangulin A (emodin-6-O-a-L-rhamnoside), physcion, rhein, sennoside A, sennoside B (sennoside A and sennoside B are stereoisomers and rhein-dianthrone diglycosides in which β-D-glucose units are bound to the OH groups of rhein anthrones at their 8th positions) were tested on MCF-7, SK-BR-3, MDA-MB-468, and MDA-MB-231 breast cancer cells and on H9c2 healthy rat cardiac myoblast cells in terms of their cytotoxicity and toxicity, respectively. A resazurin reduction assay was used to determine the cytotoxicity. Among the tested compounds, two naphthoquinone derivatives alkannin and juglone exhibited remarkable cytotoxicity on breast cancer cells and exhibited alleviated toxicity profiles on healthy cells deserving further investigation as possible drug candidates against breast cancer. Structure-activity relationships of these compounds were also evaluated and discussed. Alkannin and juglone, which are naphthoquinone derivatives isolated from natural sources, may be promising agents in the development of drug-candidate molecules with increased efficacy and safety for breast cancer.